Celyad Oncology SA Logo

Celyad Oncology SA

ISIN: BE0974260896 | Ticker: CYAD | LEI: 549300ORR0M8XF56OI64
Sector: Health CareSub-Industry: Biotechnology
Country: Belgium

About Celyad Oncology SA

Company Description

Celyad Oncology is a biotechnology company focused on the research and discovery of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Year founded

2004

Served area

Worldwide

Headquarters

Axis Business Park Rue Edouard Belin 2, 1435 Mont-Saint-Guibert, Brabant wallon – Belgium

Financial statements

Download as Excel
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 66,084,000.00 79,943,000.00 19,716,000.00
Noncurrent Assets N/A 46,379,000.00 45,651,000.00 4,891,000.00
Property Plant And Equipment N/A 4,119,000.00 3,248,000.00 309,000.00
Noncurrent Receivables N/A 2,117,000.00 2,209,000.00 0.00
Other Noncurrent Assets N/A 293,000.00 262,000.00 264,000.00
Current Assets N/A 19,705,000.00 34,292,000.00 14,825,000.00
Trade And Other Current Receivables N/A 615,000.00 668,000.00 1,118,000.00
Cash and cash equivalents 39,338,000.00 17,234,000.00 30,018,000.00 12,445,000.00
Shortterm Investments Classified As Cash Equivalents N/A 0.00 0.00 0.00
Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners N/A N/A 0.00 245,000.00
Other Current Assets N/A 1,711,000.00 2,211,000.00 1,017,000.00
Equity And Liabilities N/A 66,084,000.00 79,943,000.00 19,716,000.00
Equity 45,619,000.00 30,994,000.00 43,639,000.00 4,317,000.00
Issued Capital N/A 48,513,000.00 78,585,000.00 78,585,000.00
Retained Earnings N/A -283,039,000.00 -308,997,000.00 -349,947,000.00
Share Premium N/A 43,349,000.00 6,317,000.00 6,317,000.00
Other Reserves N/A 30,958,000.00 33,172,000.00 34,800,000.00
Capital Redemption Reserve N/A 191,213,000.00 234,562,000.00 234,562,000.00
Noncurrent Liabilities N/A 23,256,000.00 22,477,000.00 4,973,000.00
Noncurrent Provisions For Employee Benefits N/A 614,000.00 53,000.00 13,000.00
Noncurrent Advances N/A 4,220,000.00 5,851,000.00 4,584,000.00
Other Noncurrent Liabilities N/A 371,000.00 164,000.00 258,000.00
Longterm Borrowings N/A 0.00 0.00 0.00
Current Liabilities N/A 11,834,000.00 13,827,000.00 10,426,000.00
Trade And Other Current Payables To Trade Suppliers N/A 4,736,000.00 6,611,000.00 4,752,000.00
Current Advances N/A 371,000.00 362,000.00 437,000.00
Other Current Liabilities N/A 5,614,000.00 5,952,000.00 5,100,000.00
Line item in (eur) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 5,000.00 0.00 0.00
Other Income 4,731,000.00 4,909,000.00 9,360,000.00
Profit Loss From Operating Activities -16,987,000.00 -26,391,000.00 -40,857,000.00
Finance Income 217,000.00 144,000.00 185,000.00
Finance Costs 434,000.00 255,000.00 198,000.00
Profit Loss Before Tax -17,204,000.00 -26,502,000.00 -40,870,000.00
Income Tax Expense Continuing Operations 0.00 10,000.00 65,000.00
Profit (loss) -17,204,000.00 -26,512,000.00 -40,935,000.00
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -17,204,000.00 -26,512,000.00 -40,935,000.00
Adjustments For Provisions N/A 858,000.00 29,000.00 2,171,000.00
Adjustments For Sharebased Payments N/A 2,782,000.00 2,172,000.00 1,624,000.00
Other Adjustments For Noncash Items N/A -933,000.00 328,000.00 -1,447,000.00
Cash Flows From Used In Operating Activities N/A -27,665,000.00 -26,643,000.00 -28,010,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 150,000.00 331,000.00 123,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 169,000.00 62,000.00 0.00
Cash Flows From Used In Investing Activities N/A 157,000.00 -126,000.00 7,202,000.00
Proceeds From Issuing Shares N/A 0.00 36,568,000.00 -124,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 429,000.00 280,000.00 230,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 1,255,000.00 1,099,000.00 896,000.00
Proceeds From Government Grants Classified As Financing Activities N/A 7,272,000.00 4,369,000.00 4,491,000.00
Cash Flows From Used In Financing Activities N/A 5,396,000.00 39,521,000.00 3,241,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A 8,000.00 32,000.00 -6,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A -22,112,000.00 12,752,000.00 -17,567,000.00
Cash and cash equivalents 39,338,000.00 17,234,000.00 30,018,000.00 12,445,000.00

Please note that some sums might not add up.

Filings & Publications

2022

Report
Q1
H1
Q3
FY
Consolidated Report
ENG / FRA
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2021

Report
Q1
H1
Q3
FY
Consolidated Report
ENG / FRA
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

BE0974260896

LEI

549300ORR0M8XF56OI64

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Euronext Brussels

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.